It may enable the targeted delivery of antisense oligonucleotides (ASOs) to neurons for reducing Tau protein, a key driver of intraneuronal neurofibrillary tangle formation in Alzheimer's disease. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.